Why Is Ocular Therapeutix Stock Gaining Monday?
Ocular Therapeutix stock jumps 6% as rival EyePoint misses Phase 3 primary endpoint for wet AMD treatment Duravyu.
Stocks · News reference
Ocular Therapeutix Maps Regulatory Strategy For Lead Drug Program
Ocular outlines FDA-aligned AXPAXLI NDA plan for wet AMD by Q4 2026, revises SOL-R study design, and streamlines DR program.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
H World Group Posts Upbeat Q2 Results, Joins Almonty Industries, Diana Shipping And Other Big Stocks Moving Higher On Monday
H World Group (HTHT) beats earnings and raises sales guidance, shares jump 8.1%. Other big gainers include ANGX, ARGX, and MESO.
8-K filing — OCULAR THERAPEUTIX, INC (OCUL)
Filed: 2026-08-03 AccNo: 0001104659-26-089443 Size: 350 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Ocular Therapeutix Q2 EPS $(0.35) Beats $(0.40) Estimate, Sales $13.475M Beat $13.199M Estimate
Ocular Therapeutix (NASDAQ:OCUL) reported quarterly losses of $(0.35) per share which beat the analyst consensus estimate of $(0.40) by 10.26 percent. This is a 10.26 percent increase over losses of $(0.39) per share
Vertex vs. Regeneron: Which Biotech Giant Is the Better Buy Right Now?
The biotech industry is experiencing a strong rebound in 2026. While both Vertex Pharmaceuticals and Regeneron are attractive options, Vertex emerges as the better buy due to its stronger competitive advantage in cystic fibrosis drugs with patent protection until the late 2030s, diversified pipeline targeting high-need areas with less competition, and lower execution risk compared to Regeneron's dependence on weight-loss candidates and defending its Dupixent franchise against increasing competition.
World Health Organization Director General Determined That The Ebola Epidemic In DRC Still Meets Criteria Of Public Health Emergency Of International Concern, But Not Those Of A Pandemic Emergency
https://www.who.int/news/item/28-08-2026-second-meeting-of-the-ihr-emergency-committee-on-the-epidemic-of-ebola-bundibugyo-virus-disease-in-the-democratic-republic-of-the-congo---meeting-report